Studies balloon pulmonary angioplasty in people with chronic thromboembolic pulmonary hypertension
Studies a balloon procedure for narrowed lung arteries in adults with chronic thromboembolic pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Key facts
- Where
- Beijing, ChinaSee the 2 sites
Where in China
- center of pulmonary vascular disease, Fuwai hospitalBeijing, ChinaTaking people
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Pulmonary Vascular Disease Research Group
- Trial code
- NCT04206852
- Record updated
- 24 September 2026
- Original description
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.Read full original descriptionShow less
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.
The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.
Inclusion: diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines; Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH; Not amenable to pulmonary endarterectomy; Willing to provide informed consent.
Exclusion: Patients unwilling or unable to provide written consent for participation in the study; Impossible to follow up.